A study dubbed TREAT -- Trial to Reduce Cardiovascular Events with Aranesp Therapy -- found the drug had little effect on the heart health of patients with chronic kidney disease compared with patients who got placebos, Thousand Oaks, California-based Amgen said in a statement. The results showed more Aranesp users suffered strokes than did patients taking placebos.
Wednesday, August 26, 2009
Amgen - Aranesp: clinical trials, ain't they a bitch!
Amgen ’s anemia drug Aranesp didn’t help the heart health of patients with chronic kidney disease, a company-sponsored trial found.
A study dubbed TREAT -- Trial to Reduce Cardiovascular Events with Aranesp Therapy -- found the drug had little effect on the heart health of patients with chronic kidney disease compared with patients who got placebos, Thousand Oaks, California-based Amgen said in a statement. The results showed more Aranesp users suffered strokes than did patients taking placebos.
A study dubbed TREAT -- Trial to Reduce Cardiovascular Events with Aranesp Therapy -- found the drug had little effect on the heart health of patients with chronic kidney disease compared with patients who got placebos, Thousand Oaks, California-based Amgen said in a statement. The results showed more Aranesp users suffered strokes than did patients taking placebos.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment